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Abstract: The acidic tumour microenvironment is now recognized as a tumour phenotype that drives
cancer somatic evolution and disease progression, causing cancer cells to become more invasive
and to metastasise. This property of solid tumours reflects a complex interplay between cellular
carbon metabolism and acid removal that is mediated by cell membrane carbonic anhydrases and
various transport proteins, interstitial fluid buffering, and abnormal tumour-associated vessels. In the
past two decades, a convergence of advances in the experimental and mathematical modelling of
human cancers, as well as non-invasive pH-imaging techniques, has yielded new insights into the
physiological mechanisms that govern tumour extracellular pH (pHe). In this review, we examine
the mechanisms by which solid tumours maintain a low pHe, with a focus on carbonic anhydrase
IX (CAIX), a cancer-associated cell surface enzyme. We also review the accumulating evidence that
suggest a role for CAIX as a biological pH-stat by which solid tumours stabilize their pHe. Finally,
we highlight the prospects for the clinical translation of CAIX-targeted therapies in oncology.
Keywords: cancer microenvironment; tumour pH; carbonic anhydrase IX; cancer metabolism; pH-stat;
pH measurement in vivo; magnetic resonance spectroscopy; models of tumour pH regulation
1. Introduction
The pH of extracellular fluid (pHe) in healthy tissues is tightly regulated between 7.35 and 7.45,
in order to sustain normal physiology and cellular metabolism. In contrast, the pHe of cancers is acidic,
between 6.3 and 7.0, reflecting the dysregulation of the acid-base homeostatic mechanisms that operate
within solid tumours.
Almost a century ago, Otto Warburg published his seminal observation, termed aerobic glycolysis,
in which tumour slices metabolized glucose into lactic acid instead of CO2, even in the presence of
oxygen [1]. This observation, now termed ‘The Warburg Effect’ gave rise to the erroneous assumption
that lactic acid produced by cancer cells would tend to acidify their cytoplasm and thus lower their
intracellular (pHi) [2,3]. Microelectrode studies on solid tumours appeared to support the assertion that
tumours were acidic, and for half a century it was believed that both their pHi and their pHe were acidic.
That dogma was overturned by the first magnetic resonance spectroscopy (MRS) studies on cancer in
the early 1980s [4–6], which demonstrated that the pHi of solid tumours, both in animal models and in
patients, was usually on the alkaline side of neutrality, much like that of normal cells. Subsequent
MRS studies using extracellular pH probes, such as 3-aminopropylphosphonate (3-APP) [7] and the
imidazole probes 2-imidazole-1-yl-3-ethoxycarbonyl propionic acid (IEPA) [8] and (±)2-(imidazol-1-yl)
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succinic acid (ISUCA) [9], firmly established the conclusion that it was the extracellular, interstitial
space of tumours that was acidic, with typical pHe values of 6.3–7.0.
In the last two decades, the acidic tumour microenvironment has become recognized as a
feature of the tumour phenotype that drives the progression of cancer. It modulates several steps
along the spectrum from preneoplasia to neoplasia, and then along the invasion–metastasis cascade,
thus conferring an evolutionary advantage on solid tumours. Several reviews have discussed aspects
of this process [10–12]. In parallel, advances in imaging technology, biophysics and chemistry have
converged with the progress in experimental modelling of human cancers to yield novel insights into the
mechanisms that cause and regulate the acidic tumour pHe; the enzyme carbonic anhydrase IX (CAIX)
has been found to play a key role in these mechanisms. From a clinical perspective, the acidic tumour
pHe is also an emerging diagnostic and therapeutic target. While current targeted therapies in oncology
mostly focus on precise molecular targets such as receptor tyrosine kinases [13,14], microRNAs [15,16],
or the ubiquitin–proteasome pathway [17,18], the acidic tumour pHe is an attractive target because
it is a common phenotype that is found across a wide spectrum of cancers. In this review, we will
discuss the common imaging techniques and their applications in various experimental models of
cancer. We will also highlight the experimental findings that inform how CAIX regulates tumour pHe,
and discuss the implications of these findings concerning the pathophysiology of disease progression.
2. Methods for Measuring Tumour pH
Techniques for measuring pH in living systems are central to the study of tumour pHe. They have
been extensively reviewed elsewhere [19,20]; however, we will briefly introduce some of the major
techniques to facilitate our subsequent discussion concerning their applications in cancer models.
The first measurements of tissue pH in vivo used microelectrodes, which measure the
potential differences of solutions with differing proton concentrations across a thin glass membrane.
The electrodes used in living tissues are much larger than cells, so they mainly measure pHe.
The principle disadvantage of microelectrode pH measurement is that it is invasive and causes damage
to cells.
Today, many non-invasive imaging modalities have been developed to measure tissue pH,
including magnetic resonance, fluorescence imaging, positron emission tomography (PET) and
single-photon emission computerized tomography (SPECT). They rely on a variety of mechanisms to
generate image contrast, and have a wide range of spatial resolution. While these techniques have
been useful in the preclinical setting, none of them have entered routine medical use, although efforts
are underway to translate some of them into the clinic. Table 1 summarizes the range of non-invasive
or minimally invasive techniques available for measuring tissue pHe.
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Table 1. Summary of the non-invasive techniques for measuring tissue pH.
Imaging Technique Description
Fluorescence imaging
Various fluorescent dyes and proteins exhibit a
wavelength shift upon protonation. Ratiometric
measurement of the fluorescent output at each
wavelength allows the calculation of pH.
Advantage: very high spatial resolution (<1 µm)
enables the measurement of subcellular pH gradients
Disadvantage: low penetration of the tissue limits its
use in whole animal and clinical imaging.
The use of SNARF-1 fluorescent dye on tumours grown
in dorsal window chamber models has enabled the
in vivo imaging of tumour pH [21,22].
Magnetic resonance spectroscopy
MRS measures the pH-dependent chemical shift of
MRS-visible nuclei such as 1H, 31P, and 19F in
endogenous or exogenous compounds.
In compounds with pKa close to the physiological
range, this property can be exploited to measure pH by
comparing the chemical shift of the pH-sensitive peak
with a previously constructed titration curve of
chemical shift vs. pH.
31P MRS can be used to measure pHi from the chemical
shift of endogenous inorganic phosphate, while pHe
can be measured with the use of
3-aminopropylphosphonate (3-APP). However, because
of the low sensitivity of the 31P nucleus, this technique
has poor spatial resolution, and cannot be used to
generate pHe maps [7,23,24].
19F MRS can be used to measure pHe with ZK-150471
(3-[N-(4-fluoro-2-trifluoromethylphenyl)-sulfamoyl]-
propionic acid) and fluorinated vitamin B6 derivatives
(6-fluoropyriodoxol & 6-fluoropyridoxamine) [25].
1H magnetic resonance spectroscopic imaging (MRSI)
of the imidazole-containing compounds,
(±)2-(imidazol-1-yl)3-ethoxycarbonylpropionic acid
(IEPA) [8] and (±)2-(imidazol-1-yl) succinic acid
(ISUCA) [9] can be used to generate pHe maps with a
spatial resolution of 1–2 mm. However, the poor
temporal resolution of 10–30 min precludes
measurement of pH changes.
Hyperpolarised (HP) 13C MR imaging
Dissolution dynamic nuclear polarization (d-DNP)
results in a substantial increase in the magnetic
resonance (MR) signal [26], allowing measurements of
spatial and temporal changes in pHe from exogenously
administered hyperpolarized molecules.
Tumour pHe can be measured with hyperpolarized
H13CO3− using the ratio of the peak intensities of
H13CO3−and 13CO2 [27].
However, this technique is dependent on carbonic
anhydrase activity, and in tissues with low carbonic
anhydrase activity, the measured pH will tend to be
overestimated [28].
pHi can be quantified from HP 13CO2 produced from
[1-13C] pyruvate in organs with a high pyruvate
dehydrogenase flux, e.g., the heart [29]. The short T1 of
[13C] bicarbonate limits spatial resolution [27]. The
current resolution of 2–10 mm is coarser than that of
some other MR imaging approaches.
Other 13C-labelled compounds have been shown to be
able to measure in vivo pHe using HP 13C MRS:
N-(2-acetamido)-2-aminoethanesulfonic acid (ACES)
[30], diethylmalonic acid (DEMA) [31], zymonic acid
[32], and amino acid derivatives [33].
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Table 1. Cont.
Imaging Technique Description
Chemical exchange saturation transfer (CEST)
CEST measures pHe from the relative rates of
protonation and deprotonation of amide functional
groups on either endogenous molecules or
administered contrast agents. It has the advantage of
high spatial resolution (0.1–2 mm) but has
low sensitivity.
AcidoCEST is a CEST-based method of measuring pHe
based on exogenous contrast agent administration [34].
Iopidamol, a United States Drug and Food Agency
(FDA)-approved contrast agent, has been used with
this approach to measure pHe in metastatic ovarian
cancer tumour models [35].
MR relaxometry
pH is measured from paramagnetic contrast agents
with a pH-dependent change in T1 relaxation time.
It has the advantage of high signal-to-noise ratio and
spatial resolution (0.2–2 mm). However, to accurately
measure the pH, this technique requires the
administration of a second pH-insensitive agent to
correct the concentration of the pH-sensitive agent.
An example of the agent is GdDOTA-4AmP5−,
a pH-dependent chelate which has been used together
with a pH-independent analogue, GdDOTP5−,
to generate high spatial resolution maps of tissue pHe
in a rat glioma model [36].
PET/SPECT imaging
In vivo pHe imaging using positron emission
tomography (PET) has been achieved using
11C-dimethyloxazolidinedione (DMO) [37], 11CO2 [38],
and 123I-labeled derivatives of malonic acid [39].
pH (low) insertion peptides (pHLIP) is a class of
acid-targeting peptides that are activated to insert
across the membrane of cancer cells by the acidity at the
cell surface. These peptides can be conjugated with
64Cu to target the radioisotope to regions where the
pHe is below 7.0 [40].
Caged derivatives of 18F-fluorodeoxyglucose (FDG) can
be localized to tumours by the release of the caging
group in low pHe, followed by uptake via glucose
transporters [41].
PET-based techniques are readily implemented with
good spatial resolution (1–2 mm). A limitation of this
approach is that it cannot measure absolute pH, and
only indicates regions below a certain pHe threshold.
pH values can be estimated from arterial blood
sampling and model fitting, but these values have not
been correlated with microelectrode measurements.
3. Experimental Cancer Models for the Study of Tumour pH Regulation
To gain insight into tumour pHe regulation in vivo, imaging techniques have to be deployed on
cancer models ranging from traditional monolayer cell cultures to mouse models and human patients.
The measurement of tumour pHe becomes more challenging as the complexity and physiologic
relevance of the model system increase.
Two-dimensional (2D) monolayer cell cultures have traditionally been the workhorse of
cancer research, and most early studies on cancer pH regulation were done in this system.
However, the extracellular environment within the monolayer cultures does not reflect the tumour
microenvironment in vivo, not least because H+, CO2 and HCO3− can freely diffuse between the
cells and the relatively huge volume of culture medium [42,43]. In contrast, the cancer cells in solid
tumours co-exist in a disorganized tissue architecture with stromal fibroblast cells and various immune
cells, all of which derive their blood supply from an abnormal tumour-associated vasculature [44].
The restricted diffusive capacity of H+, CO2 and HCO3− in the extracellular space of solid tumours [45]
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causes spatiotemporal heterogeneity of oxygenation and cellular metabolism, resulting in gradients of
pHe that will not occur in 2D cell cultures.
In vitro 3D cell spheroid systems simulate some aspects of the spatial architecture and cell-to-cell
contact found in solid tumours in vivo and provide a tractable platform to study the role of several
cell physiological processes in regulating the tumour microenvironmental pH [43]. Spheroids are
cell cultures in which cells are grown in clusters or aggregates, typically without the addition of
the extracellular matrix or growth factors to the culture medium, or by growing cell clusters in
low-attachment culture plates. Optical imaging by pH-sensitive fluorescent dyes can be used to
measure spatial gradients of pHi and pHe in these spheroid models.
More recently, the application of organoid technology from the field of stem cell research has led
to the development of cancer organoids—microscopic self-organizing, 3D structures that recapitulate
many of the structural and functional aspects of tumours in vivo [46]. The cancer cells are embedded
in a 3D matrix such as a collagen or basement membrane, sometimes with the addition of growth
factors that promote growth as a 3D structure. Such organoids can also be co-cultured with fibroblasts
and immune cells, thus recreating something of the cellular heterogeneity found within solid tumours.
These organoids are increasingly used in the study of tumour metabolism and pH regulation, and they
present an improvement over tumour spheroids in modelling in vivo tumour physiology [47,48].
However, tumour pH regulation cannot be fully modelled in culture, even by using tumour
spheroids and organoids. Cancer cells in solid tumours are genetically heterogeneous, and they
co-exist with non-transformed stromal and immune cells within an unknown nutrient and O2 milieu,
with further differences due to tumour stage and exposure to therapy. While in situ tumours within
patients remain the gold standard for studying tumour pHe, animal models allow studies of gene and
protein function by analysing the phenotypes that arise after silencing or overexpressing particular
genes. Animal models for studying cancer biology differ in their complexity and their degree of
fidelity to human cancers [49]. They include genetically engineered mouse models (GEMMs) that
develop tumours in situ, as well as allograft models and xenograft models derived from human
tumours (patient-derived xenografts) or cancer cell lines. These in vivo models come closer to
the physiological complexity of human cancers than cell culture preparations, and they also allow
interactions between the tumour and normal host tissues. Nonetheless, the interpretation of the data
from mouse models must have the caveat that factors such as diet, strain, sex, age, husbandry and
environmental stressors can affect metabolism of the host animal, and thus the metabolism of the
tumour [50,51]. Moreover, pH regulation studies in such model systems are restricted by the currently
available imaging techniques, which have limited sensitivity, reproducibility and spatiotemporal
resolution, and face challenges with the targeting and accessibility of pH probes.
4. Why Is Tumour pHe Acidic?
For many years, it was believed that the increased lactate metabolic flux and extrusion of this
acidic metabolite from cancer cells explained tumour extracellular acidification. This simple model
assumed that lactic acid exported from cancer cells into the interstitial fluid accumulates because it
cannot be transported away rapidly enough to the blood vasculature, and that acidification ensues
because of the poor buffering capacity of the extracellular fluid.
Early evidence to challenge this concept came from a series of studies by Tannock and colleagues in
the 1990s, which found that tumours derived from glycolysis-deficient Chinese Hamster fibroblasts, that
lacked both the phosphoglucose isomerase enzyme and a number of glucose transporters, surprisingly
had an acidic pHe in vivo, even though negligible amounts of lactic acid were formed and these cells
were not able to acidify the culture media in vitro [52]. This finding was replicated using Chinese
Hamster ovary cells lacking lactate dehydrogenase, which also showed minimal lactic acid production
in vitro but were nonetheless capable of producing tumours with acidic pHe when transplanted
in vivo [53]. One possible explanation for this unexpected result would be that these mutant cells
produced large amounts of CO2 by oxidative metabolism. In fact, earlier studies by Gullino et al.,
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sampling interstitial fluid from solid tumours grown in ‘Gullino’ PTFE chambers, showed that the
tumour interstitial fluid of numerous tumour types contained high levels of CO2 [54].
Numerous studies on cancer metabolism over the past decade have revealed that cancer cells
exhibit aerobic glycolysis due to the activation of oncogenes, the loss of tumour suppressor genes,
and the upregulation of the PI3K pathway, and that one advantage of these high glycolytic rates is the
availability of precursors for anabolic pathways, that are needed for the biosynthesis of cellular building
blocks during proliferation [55,56]. While this Warburg effect has been observed in many human
cancers (and is indeed the basis by which FDG-PET scans operate), studies have demonstrated that
human cancers show distinct metabolic heterogeneity [57] and produce most of their metabolic energy
through glucose oxidation via the tricarboxylic acid cycle, resulting in the formation of CO2 [58–60].
By sampling the blood entering and exiting solid tumours in vivo, it is possible to calculate their
outputs of lactic acid and of CO2. Such calculations have been performed on both animal models and
tumours in patients, and they have found that the tumour CO2 output is comparable to or greater
than that of lactate. Kallinowksi et al. studied a tumour xenograft model in which human tumour
xenografts were grown in nude rats, on pedicles containing the epigastric artery and vein, and were
prevented from acquiring other vasculature by polyethylene sheaths [61,62]. This defined blood
supply allowed measurement of the blood flow and assay of metabolite concentrations from the artery
supplying and the veins draining the tumour. Holm et al. performed similar balance studies on human
colon carcinomas during bowel resection surgery, by cannulating the mesenteric vessels supplying
these tumours and measuring the metabolites in blood from the mesenteric artery and vein [63].
Calculations of the production of CO2 from the substrate balance data reported by Kallinowski et al.
found that human xenografts in nude rats produced 588–850 nmol/g/min CO2 vs. 527 nmol/g/min lactate,
and similar calculations from the data in Holm et al. found that colonic tumours in human patients
produced five times more CO2 than lactate, 1296 nmol/g/min CO2 vs. 220 nmol/g/min lactate [64].
These balance studies suggested that solid tumours in vivo synthesised most of their ATP by oxidative
metabolism (because the complete oxidation of glucose to CO2 phosphorylates 16 times the amount of
ATP obtained from glycolysis to lactate [65]), and they did not support the dogma that cancer cells
rely on aerobic glycolysis for their energetic requirements or that tumour extracellular acidification is
entirely due to lactate extrusion.
However, although these in vivo studies suggest that CO2 will be a significant source of metabolic
acid production in cancer cells, the higher pK of carbonic acid (pKa 6.35) compared to that of lactic
acid (pKa 3.86) means that, on a mole for mole basis, CO2 would have a much smaller acidifying
effect than lactic acid. This suggests that in order for CO2 to be a significant source of acidity in the
tumour extracellular space, there must be an additional mechanism in play, such as one to accelerate
the hydration of CO2 to form H+. In the next section of this review, we explore how CAIX provides
such an additional mechanism and thus maximises the locally acidifying effect of CO2 production.
5. Carbonic Anhydrase IX and Its Role in Cancer Biology
The role of the enzyme CAIX is central to understanding how CO2 production leads to the
acidification of the tumour interstitial space. CAIX belongs to a family of zinc metalloprotein enzymes
that catalyse the reversible interconversion of CO2 to form HCO3− and H+ [66]. In mammals, there are
16 isoforms of carbonic anhydrases, which differ in their activity and cellular localization [67]. Cancer
cells primarily express the plasma membrane-associated carbonic anhydrases, CAIX and CAXII [68–70],
as well as intracellular carbonic anhydrases such as CAI [71,72] and CAII [73–75]. CAIX has been
extensively studied as a potential therapeutic target in oncology, owing to its specificity to cancer
cells—it has a very restricted expression in the normal stomach and gut epithelial cells [76] but is
strongly upregulated in many different types of tumour tissue [77]. Several preclinical studies have
suggested that the inhibition of the CAIX function delays the growth of tumours [78–80] and reduces
invasion and metastasis under experimental conditions [79].
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CAIX is a protein that is tethered to the cell surface membrane. It is comprised of an extracellularly
facing catalytic domain, an N-terminal proteoglycan-like (PG) domain, a single transmembrane domain
and a short intracellular C-terminal tail [70]. The N-terminal PG domain is unique to CAIX within
the CA family [81] and has been shown to be important in the assembly of focal adhesion contacts
during cell migration [82,83], and as a buffer for protons to support the catalytic activity of the
enzyme [84]. Recent studies have also suggested that this PG domain may serve as a proton antenna
for monocarboxylate transporters, to facilitate proton-coupled lactate flux [85].
The regulation of CAIX expression has been linked not only to the hypoxic tumour
microenvironment, but also to genetic mutations, and dysregulated growth factor signalling pathways.
In hypoxia, CAIX expression is mainly upregulated by the stabilization of the hypoxia inducible
transcription factors (HIF) and the activation of the HIF signalling pathway. The HIF signalling pathway
has been extensively reviewed elsewhere [86,87]. Briefly, HIF-1 is a heterodimeric transcription factor
that is composed of an O2-regulated HIF-1α subunit and a constitutively expressed HIF-β subunit [88].
In the presence of oxygen, the tumour suppressor von Hippel–Lindau (pVHL) protein targets HIF-1α
for proteasomal degradation by means of proline hydroxylation using O2 and α-ketoglutarate as
substrates [89]. Most notable amongst the HIF target genes are the vascular endothelial growth factor
(VEGF) [90], carbonic anhydrase 9 (CA9) [68], and components of metabolic pathways such as lactate
dehydrogenase-A (LDHA) [91] and glucose transporters (GLUT1) [92,93]. Of these, CA9, the gene
encoding CAIX, is one of most responsive genes to hypoxia because the hypoxia response element
(HRE) sequence of this gene is localized just upstream of the transcription initiation site [94]. Due to
the tight regulation by HIF-1, CAIX is predominantly expressed in regions of chronic hypoxia within
solid tumours [68].
Mutations and dysregulated signalling pathways in cancers have been mechanistically linked
to the regulation of CAIX expression via hypoxia-independent activation of HIF. The most notable
example would be the inactivation mutations of the von Hippel–Lindau tumour suppressor (VHL)
gene which lead to the constitutive activation of HIF signalling and CAIX expression in clear cell renal
cell cancers (ccRCCs) and the von Hippel–Lindau syndrome hemangioblastomas [95,96]. Besides this,
HIF-1α expression and signalling are also regulated by major signal transduction pathways, including
those that involve phosphatidylinositol 3-kinase (PI3K) [97] and extracellular signal-regulated kinase
(ERK)/mitogen-activated protein kinase (MAPK) [98,99] and upstream tyrosine kinases such as SRC
and RET [100,101]. Mutations in other tumour suppressor genes such as PTEN, PML and TSC activate
HIF by promoting its translation [102–104]. Less common activators of HIF are mutations in the
Krebs cycle enzymes, fumarate hydratase and succinate dehydrogenase [105–107], where the resulting
increased levels of fumarate or succinate act as 2-oxoglutarate analogues to inhibit pVHL prolyl
hydroxylation, thereby activating HIF signalling [108,109].
CAIX is expressed in a wide variety of solid tumours, including breast [110,111], colorectal [112],
glioblastoma [113], lung [114], head and neck [115,116], and cervical cancers [117]; its expression
is typically associated with poor disease prognosis [110–117]. The correlation between CAIX
expression and poor prognosis can be mechanistically explained by CAIX protecting the cancer
cell from intracellular acidosis, allowing rapid tumour growth, and creating extracellular acidosis,
which promotes cancer cell migration and invasion. Both catalytic and non-catalytic CAIX-associated
mechanisms allow cancer cells to progress along the invasion–metastasis cascade and thus to seed
distant metastatic outgrowths [83,118–120].
CAIX expression has been shown to have an important role in the regulation and maintenance
of cancer stem cells (CSCs), a small but distinct subpopulation of cancer cells within a solid tumour
that are capable of regenerating the tumour. CSCs exhibit many of the properties of stem cells
including clonogenicity, self-renewal, quiescence, and the ability to undergo epithelial-to-mesenchymal
transition (EMT) [121,122]. In addition, CSCs have been shown to preferentially survive within
hypoxic niches [123,124]. In the first study to report a link between CAIX and cancer stem cells,
Lock et al. demonstrated that CAIX expression is required for the enrichment and function of breast
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CSCs in hypoxia, and that CAIX is required for mTOR signalling under hypoxia [125]. Intriguingly,
CAIX expression was found to regulate the expression of ‘stemness’ genes such as Snail and Notch,
and genes involved in the EMT; additionally, the inhibition of CAIX by small-molecule inhibitors
depleted CSCs from tumours in vivo, reducing tumour growth and metastasis in preclinical models of
cancer [125]. Ledaki et al. showed that subpopulations of cancer cells with hypoxia-inducible CAIX
expression are enriched with cells that show high self-renewal capacity and express cancer stem cell
markers. They also showed that the differential induction of CAIX under hypoxia is due to epigenetic
regulation which induces differences in chromatin structure [126]. While these studies suggest that
CAIX may be an important therapeutic target for selectively depleting CSCs, it remains unknown
whether the effect of CAIX in CSCs is mediated through its role as a regulator of tumour pHe.
CAIX catalyses the reversible hydration of CO2 at its exofacial site on the cell surface membrane,
thereby placing it in a central position to regulate tumour pHe, and indirectly, pHi (Figure 1). To study
the effect of CAIX on pHe and pHi, Swietach et al. employed confocal imaging using fluorescent pH
dyes on 3D spheroid models of RT112 renal cancer cells [127] and HCT116 colorectal cancer cells [45],
both of which overexpress CAIX. CAIX overexpression intensified the core-to-periphery pHi and pHe
gradients of the spheroids, rendering the pHi of cells at the core less acidic, but making the peripheral
pHe more acidic [45,127]. By the computational modelling of the data from their spheroid studies,
they showed that CAIX maintains a steep outward-directed CO2 gradient across the plasma membrane,
accelerating the CO2 excretion, and that this results in extracellular acidification and a more alkaline
pHi [45]. Mathematical modelling of this reaction in vivo suggested that the hydration of CO2 at the
extracellular surface of the cell membrane also allows the parallel diffusion of CO2, HCO3− and H+
across the interstitial space into the nearest blood vessel [45]. CAIX was predicted to exert an effect on
the pHi and pHe in poorly perfused but metabolically active tissues, with the extracellular CO2/HCO3−
buffer system driven out of equilibrium [45]. The effect of CAIX on pHe will depend on the type of
acid released across the cell membrane, and the greatest acidifying effect would be observed if the cell
metabolized glucose completely to CO2 [45]. In contrast, the greatest alkalinizing effect would occur if
all the glucose was metabolized into lactic acid, without any neutralisation of the lactic acid by the
HCO3− to form lactate- and H+ [45].
Hypoxic cancer cells display CAIX on their extracellular membrane but also have intracellular
carbonic anhydrases such as CAII. This would allow them to extrude the H+ that is formed by
the dissociation of the lactic acid product of anaerobic glycolysis, by using a Jacobs–Stewart Cycle
(Figure 2) [128]. Bicarbonate, formed by the mechanism shown in Figure 1, is transported by the
Na+/HCO3− cotransporter into the hypoxic cell, where, under catalysis by CAII, it binds to H+, forming
CO2 and H2O. The CO2 then diffuses through the cell membrane into the extracellular space where
CAIX on the extracellular surface catalyses its hydration to HCO3− and H+; thus, an equivalent amount
of H+ that was originally in the hypoxic cell is now in the extracellular fluid. Excess CO2 from the
cancer tissue will diffuse to host capillaries.
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Figure 1. Carbonic anhydrase IX (CAIX) links tumour energy metabolism to its pH regulation.
1. The major by-product of oxidative energy etabolism, CO2 diffuses across the cell membrane
lipid bilayer into the extracellular space, along its concentration gradient; 2. On the extracellular
surface of the cell membrane, the exofacial catalytic domain of CAIX catalyses the hydration of CO2 to
form H+ a d HCO3−; 3. In parallel, lactate, the end-product of glycolysis, exits the cell through the
monocarboxylate transporter at a rate that is influenced by the pH gradient across the cell membrane
(pHi–pHe gradient). GLUT, gluc se transporter; MCT, monocarboxylate transporter.
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6. Discovery of the Tumour Extracellular pH-Stat Mechanism 
Stubbs et al. previously proposed that the acidic tumour pHe reflects more than just the high 
acid output of the cancer cells, and postulated the existence of an extracellular pH homeostatic 
mechanism, a pHe-stat, that was subverted by the cancer cell to set the pHe at a constant level and 
curtail excessive pH loading [129]. While an acidic tumour pHe promotes tumour growth and 
invasion, the pHe cannot be allowed to fall too low, as over-acidification would cause cell necrosis. 
Hence, cancer cells must utilise this pHe-stat to maintain a microenvironment that is hostile to the 
surrounding normal tissues, yet favourable for their own survival. 
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Figure 2. A Jacobs–Ste art Cycle helps hypoxic cancer cells extrude + produced by anaerobic
glycolysis. 1. CO2 diffuses from the cancer cell into the extracellular space; 2. CAIX on the extracellular
surface of the hypoxic cancer cell catalyses the hydration of CO2 to form H+ and HCO3−; 3. The HCO3−
enters the hypoxic cancer cell via the Na+/HCO3− cotransporter and binds H+ from lactic acid, catalysed
by CAII, thus forming CO2; 4. The CO2 diffuses from the hypoxic cancer cell into the extracellular
space, along its concentration gradient; 5. On the extracellular surface of the hypoxic cancer cell,
CAIX catalyses the hydration of the CO2 to form H+ and HCO3−. The HCO3− provides further substrate
to repeat stage 3 of the cycle, and an equivalent amount of H+ that was originally inside the hypoxic
cancer cell (ringed in red) is now in the extracellular fluid; 6. Accumulating CO2 diffuses to a capillary.
GLUT, glucose transporter; MCT, monocarboxylate transporter; NBC, Na+/HCO3− cotransporter.
6. Discovery of the Tumour Extracellular pH-Stat Mechanism
Stubbs et al. previously proposed that the acidic tumour pHe reflects more than just the high acid
output of the cancer cells, and postulated the existence of an extracellular pH homeostatic mechanism,
a pHe-stat, that was subverted by the cancer cell to set the pHe at a constant level and curtail excessive
pH loading [129]. While an acidic tumour pHe promotes tumour growth and invasion, the pHe cannot
be allowed to fall too low, as over-acidification would cause cell necrosis. Hence, cancer cells must
utilise this pHe-stat to maintain a microenvironment that is hostile to the surrounding normal tissues,
yet favourable for their own survival.
If pHe was indeed under homeostatic control, then it should not correlate with pHi, whereas in a
model of H+ transport, in which the rate of the H+ efflux from the cells depends only on the proton
concentration in the interstitial space, there should be a tendency for pHi and pHe to be correlated.
Using 31P MRS and the extracellular pH probe 3-APP, Stubbs et al. measured pHi and pHe in a range
of rodent tumour models (RIF-1 fibrosarcoma, H9681a hepatoma and GH3 prolactinoma), and found
no correlation between the pHi and pHe values [129]. These findings supported the hypothesis that
the acidic tumour pHe is not simply a function of tumour metabolism per se, but is maintained by a
homeostatic mechanism—a cancer pHe-stat.
Several in vitro studies have suggested that the biochemical and biophysical properties of CAIX
make it suited to the role of pHe-stat. In 2009, Alterio et al. published the first x-ray crystal structure of
the catalytic domain of CAIX and showed that the presence of the proteoglycan chain at the border of
the active site of the enzyme lowered its pKa from 7.01 to 6.49, ensuring that the enzyme had better
catalytic efficiency at the acidic pH values at which it operated [130]. Using 18O exchange between
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CO2 and H2O to measure the exofacial CAIX activity in MDA-MB-231 breast cancer cells by membrane
inlet mass spectrometry, Li et al. reported the first detailed measurement of the catalytic properties
of the enzyme in its native membrane environment [131]. They found that the rate constant for the
catalytic hydration reaction was faster than for the dehydration at the physiological pH of 7.4 [131].
At pH 6.8, the rate constants for hydration and dehydration were essentially equal, and at pH values
lower than 6.8, the dehydration reaction was faster [131]. Mahon et al. reported that the catalytic
domain of CAIX exhibits biochemical and biophysical properties that create low pH stability and
activity [132]. Taken together, these findings suggest that the primary role of tumour CAIX is to utilize
the interconversion of CO2 and HCO3− in order to stabilize the pHe around 6.8, thus maintaining an
acidic pHe set-point of cancer cells in response to the proton load from cellular metabolism. Intriguingly,
the measurement of CAIX activity in vitro in HCT116 cells showed that CA activity was markedly
reduced by decreasing the pH over the pH range found in tumours, with a pK of 6.84 and a Hill
cooperativity coefficient of 2. This Hill coefficient would tend to sharpen the change in enzyme activity
with pHe, suggesting that CAIX may have been adapted to provide a pHe-stat mechanism whereby
excess acid self-limits the build-up of extracellular acid [80].
In parallel, several investigators have sought to study the effect of CAIX expression on tumour
pHe in xenograft models, using various magnetic resonance-based pHe measurement techniques.
Chen et al. employed the chemical exchange saturation transfer (CEST)-based MRI pHe measurement
technique, acidoCEST MRI, to measure tumour pHe in a range of lymphoma xenograft tumour models
(Raji, Ramos and Granta 519 cell lines) with different levels of CAIX expression [133]. The average
tumour pHe ranged between 6.78 and 6.86, but there was no statistically significant difference between
the mean pHe values of the different models. They derived a xenograft acidity score from the
percentage and magnitude of the acidity, and found a correlation between that score and the level of
CAIX expression in the tumour models, measured by histopathological staining [133]. Despite the
positive correlation, it was not possible to draw any conclusion about causality between the levels of
CAIX expression and the xenograft acidity score.
Using hyperpolarized 13C magnetic resonance spectroscopy with [13C] bicarbonate (H13CO3−),
Gallagher et al. measured the pHe of two colorectal tumour xenograft models expressing different
levels of CAIX [27]. However, while they observed a lowering of pHe in the CAIX-overexpressing
tumours, the measured tumour pHe values were alkaline, likely an overestimation error due to the
incomplete equilibration of the hyperpolarized 13C label between the H13CO3− and 13CO2 pools on
the timescale of the 13C MRS measurements. This problem arises because the accurate measurement
of pHe using the hyperpolarized 13C bicarbonate technique is dependent on the tissue having high
levels of carbonic anhydrase activity [27]. Using 13C MRS magnetization transfer to measure the rate
of exchange of hyperpolarized 13C label between bicarbonate and CO2, Gallagher et al. were able
to measure the enzymatic activity of carbonic anhydrase in their tumour models and observed that,
paradoxically, the tumours overexpressing CAIX showed a lower enzyme activity compared to the
controls [27]. The administration of bicarbonate in the drinking water of mice elevated tumour pHe
and restored enzyme activity to control levels, suggesting that the enzymatic activity of CAIX exhibits
pH dependence and can be inhibited at low pH levels, akin to a negative feedback mechanism [27].
This observation suggests the interesting proposition that CAIX expression may be increased in hypoxia
to compensate for the decreased specific activity of the enzyme at the lower pHe.
To study the regulatory effect of CAIX on the tumour pHe, Lee et al. employed a high-resolution
in vivo pH-imaging technique that was independent of the enzymatic kinetics of CAIX. Using 1H MRSI
with an extracellular pH 1H MRS probe, ISUCA, they performed high-resolution spatial mapping
of pHe in colorectal tumour xenograft models expressing different levels of CAIX, and observed
that CAIX-expressing tumours had a more acidic pHe than the control tumours [134]. Importantly,
the expression of CAIX imposed an upper limit of tumour pHe at 6.93, consistent with the hypothesis
that CAIX acts as a pH-stat to maintain the pHe at a more acidic level than the typical pHe of
7.35–7.45 [134]. Intriguingly, there was no difference in pHi values between the CAIX-expressing
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and non-CAIX expressing tumours, as measured by 31P MRS, suggesting that CAIX acidifies only
the tumour pHe and not pHi [101]. This latter observation was concordant with the earlier proposal
of Stubbs et al. [129] that if pHe was indeed under homeostatic control, then it should not correlate
with pHi. Additionally, these CAIX-expressing tumours were found to have a higher level of lactate
compared to the control tumours [134]. Calculations of the ratio of lactate on either side of the
membrane from the mean pHi and pHe values of these tumours revealed that CAIX-expressing
tumours had markedly higher intracellular lactate than non-CAIX expressing control tumours [134].
Collectively, these findings suggest that CAIX acts as a pH-stat that maintains an acidic tumour pHe.
7. Implications of an Extracellular pH-Stat for Cancer Progression
It is now well established that the acidic tumour pHe phenotype is associated with aggressive
behaviour of solid tumours. Thomlinson and Gray first reported that human tumours grew as
cords around blood vessels, and that as a tumour grows and outstrips its blood supply, its central
region becomes hypoxic, although the cells remain within the diffusion distance of glucose [135].
Hypoxia upregulates glycolysis through the activation of hypoxia-inducible factor-1 (HIF-1) which
induces the expression of glycolytic enzymes (e.g., lactate dehydrogenase A) [136], proton-exporting
active transporters, (e.g., monocarboxylate transporter 4 (MCT4) [137]), and carbonic anhydrase
IX (CAIX) [68].
These adaptations, which enable cancer cells to survive hypoxia by maintaining their intracellular
pH within the physiological range and thereby creating an acidic pHe, have also been found to promote
their invasion into normal host tissue and metastasis into other organs. Setting pHe to a constant acidic
condition may therefore be an evolutionary strategy used by cancer cells to create an environment that
fosters tumour growth and invasion in response to microenvironmental selection forces. One could
even argue that the characteristically hypoxic tumour microenvironment and the chaotic blood supply
that gives rise to it are both evolutionarily selected features that are driven by the aggressive phenotype
conferred on cancer cells by extracellular acidity.
Gatenby, Gillies and colleagues have shown that an acidic pHe promotes tumour local invasion
and metastasis, and that cancer cells are able to modulate the set point of tumour pHe in response to
microenvironmental selection pressures as an evolutionary strategy favouring invasion [21,138]. At the
cellular level, migrating cancer cells have proton-exporting machinery, such as sodium–hydrogen
exchangers (NHE1) or sodium-bicarbonate cotransporters (NBCn1), coupled to CAIX at the front of
their invadopodia, resulting in a more acidic pHe at the leading edge of the migrating cell [83,119] which
activates proteases, e.g., lysosomal cathepsins, that then degrade the host’s extracellular matrix [139,140].
Gatenby et al. initially reported in silico mathematical simulations predicting that tumours acidified
the extracellular space of normal tissue around the tumour edge [141], and confirmed these predictions
via the intravital imaging of PC3N and MCF7 tumours, grown in dorsal window chambers [21].
They measured the peritumoural H+ flow using vectors generated from pHe distribution around the
tumours, and found a general flow of tumour-derived acid from the core to the periphery, and then into
the surrounding normal tissue [21]. In another study using dorsal window chamber tumour models
and the confocal imaging of pHe with a fluorescent pH indicator, SNARF-1 Free Acid, they observed
that the acidic pHe of peritumoural tissues was coincident with the location of subsequent tumour
invasion, confirming a specific prediction of the acid-mediated invasion hypothesis [22]. The treatment
of the animals with sodium bicarbonate reduced the pH gradient and reduced the local invasion in these
tumour models [22]. Using a theoretical framework from evolutionary dynamics, Gatenby and Gillies
proposed that the metabolic properties of cancer cells and their consequent interstitial acidification
provided an evolutionary advantage that promotes tumour cell proliferation at the expense of the
surrounding normal cells [142].
Further support for the acid-mediated invasion hypothesis has come from histopathological data
showing cells at the invading edge expressing significantly more CAIX than those in the core of the
tumour. Using quantitative image analysis of histologic specimens from patients with breast cancers,
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Lloyd et al. found that the spatial distribution of CAIX was consistently higher in the invasive tumour
edge compared to the centre in all samples, which matched the predictions of evolutionary game theory
models [143]. A key assumption of their model was that CAIX was able to set the pHe at 6.8 and that it
served as a biomarker of regional tumour acidity. Thus, cancer cells are predicted to evolve towards
an evolutionarily stable state, dictated by their adaptations to changes in environmental conditions
such as blood flow and hypoxia [143]. Collectively, these studies suggest that the acidic pHe confers a
selective advantage during the somatic evolution of cancers by facilitating the invasion of cancer cells
into surrounding normal tissues.
8. CAIX as a Therapeutic Target in Oncology
CAIX is a promising therapeutic target in oncology. In vivo studies have shown that the genetic
ablation of CAIX reduced the growth rate of colon and breast cancer tumour xenografts. Using a
tetracycline-inducible system for RNA-interference, Chiche et al. reported that silencing the ca9 gene
reduced colorectal LS174Tr xenograft tumour volume by up to 40%, and that this also resulted in a
compensatory upregulation of ca12mRNA [78]. Consequently, the greatest reduction in tumour volume
was achieved through silencing both ca9 and ca12 genes. In cultured cells challenged with a CO2 load,
both CAIX and CAXII contribute to extracellular acidification and the maintenance of a more alkaline
resting pHi [78]. In a 4T1 murine metastatic breast cancer model and an MDA-MB-231 human breast
xenograft model, Luo et al. reported that shRNA-mediated the silencing of CAIX-attenuated tumour
growth; it also inhibited spontaneous lung metastasis formation in the 4T1 model [78]. The effect
on tumour growth and metastasis formation was recapitulated through the use of CAIX-specific
small molecule inhibitors, confirming the efficacy of CAIX as a targetable biomarker for cancer
therapeutics [78].
Another avenue for the use of CAIX inhibition may be as a combination therapy with antiangiogenic
drugs; this could produce additive results, since immunohistochemical data show that CAIX is part of a
resistance mechanism that enables tumours to adapt to the increased hypoxia induced by bevacizumab
treatment [80]. McIntyre et al. reported that the shRNA knockdown of CAIX in colon cancer HCT116
and U87 glioblastoma xenografts enhanced the effect of antiangiogenic therapy with bevacizumab,
resulting in a reduced tumour growth rate in vivo [80]. They also used acetazolamide to inhibit the
enzymatic activity of CAIX, which recapitulated the effects of a combination of CAIX knockdown
and bevacizumab. Like Chiche et al., they found that CAIX knockdown induced the expression of
CAXII in 3D spheroids, but not in 2D cell culture [80]. In spheroid culture and tumour xenografts,
CAIX expression was found to increase the growth rate and the expression of Ki-67, a marker of
proliferation, while at the same time promoting necrosis and apoptosis [80].
9. CAIX—Clinical Translation
There is now convincing evidence that CAIX can serve as a biomarker and/or therapeutic target in
various tumour types. To this end, a distinction can be drawn between the tumours that express CAIX as
a consequence of inactivating mutations of the von Hippel–Lindau (pVHL) tumour suppressor protein,
and tumours in which CAIX is present due to microenvironmental hypoxia. In the former group,
exemplified by clear cell renal cell carcinoma (ccRCC), more than 90% of tumours with inactivating
mutations of pVHL have a constitutive stabilization of HIF and a high percentage of tumour cells
expressing CAIX [144,145]. In more advanced ccRCC, CAIX expression decreases due to a switch from
the HIF-1 to the HIF-2 isoform, which explains why the low expression of CAIX (defined as staining
fewer than 85% of cells) in such tumours is a marker of poor prognosis [146].
In many other tumour types, such as head and neck, breast, colorectal, brain and lung tumours,
CAIX is expressed in areas that are hypoxic and/or acidic, and its expression usually increases with
increasing tumour stage and grade [68]. Immunohistochemical staining of CAIX is mostly found
at the plasma membrane, and while cytoplasmic and/or nuclear staining are also occasionally seen,
their biological significance is unclear. In addition, CAIX expression is associated with various other
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prognostic variables including c-ErbB2/Her2 [147,148], EGFR [114,149], MMP-9 [149], CD44 [150] and
Ki-67 [151]. CAIX can also be detected in tumour stroma, which is associated with poor prognosis [152].
As a consequence of ectodomain shedding and release in exosomes, CAIX can be detected in the body
fluids of cancer patients, and this can be exploited for non-invasive screening or monitoring tumour
response to therapy [153,154].
Patients with tumours highly expressing CAIX are at a higher risk of disease progression
and metastasis, independent of the tumour type or site. In a meta-analysis of studies between
2001–2015 involving more than 24,000 patients with non-RCC tumours, there was a strongly significant
association between immunohistochemical CAIX staining and several different endpoints, including
overall survival, disease-free survival, locoregional control, disease-specific survival, metastasis-free
survival, and progression-free survival [155]. Besides this, numerous studies have reported the
correlation between CAIX expression and resistance to chemotherapy [156], radiotherapy [115,157]
and immunotherapies against PD-1 [158]. These findings provide a rationale for developing prognostic
biomarkers and therapeutics based on CAIX expression.
Inhibitors of carbonic anhydrase activity as emerging anticancer therapeutics have been reviewed
elsewhere [159]. In general, therapeutic strategies targeting CAIX involve one of two approaches.
The first is based on the role of CAIX in pH regulation and uses compounds that inhibit its enzymatic
activity through binding at or near its active site. The efficacy of this approach has been demonstrated
by several preclinical studies in murine models of cancer [78–80]. Recently, SLC-0111, a small molecule
inhibitor of CAIX, successfully completed Phase I clinical trials for the treatment of advanced, metastatic
solid tumours [160]. Efforts are also underway to recruit patients for a Phase 1b trial of SLC-0111
in combination with gemcitabine in metastatic pancreatic cancer [161]. However, the clinical use
of single agent CAIX inhibitors is likely to be hindered by the cancer cell, inducing compensatory
mechanisms such as the upregulation of CAXII expression, or other acid-extruding mechanisms
such as NHE1, resulting in an unsatisfactory therapeutic effect. Therefore, a more prudent approach
would be to explore the use of anti-CAIX therapy in conjunction with other established anti-cancer
drugs. One example of this concept would be to use anti-CAIX therapy in patients undergoing
anti-VEGF therapy, since CAIX expression is upregulated as a compensatory mechanism in tumours
experiencing hypoxia as a result of anti-angiogenesis [80,162]. Besides this, CAIX inhibition can
also be used in conjunction with radiotherapy, which has been demonstrated by the use of DH348,
a nitroimidazole-based anti-CAIX inhibitor that not only reduced tumour growth in mice but also
sensitized the tumours to radiotherapy [163].
The second strategy targets CAIX by immunotherapy and exploits the tumour-associated
expression pattern of CAIX. The use of monoclonal antibodies against CAIX ensures high specificity
and selectivity that are superior to the effects of chemical inhibitors, and the quick cell-killing effect
of antibody-dependent cellular cytotoxicity (ADCC) circumvents the development of compensatory
mechanisms. Most of the studies using this strategy have been undertaken in animal models of RCC
and in patients with non-metastatic RCC, using the chimeric human-mouse monoclonal antibody G250
(RENCAREX/GIRENTUXIMAB), which is a safe, well tolerated antibody that was found to prolong
disease-free survival by up to 22 months in a subgroup of ccRCC patients with high tumour CAIX
expression [164].
In non-RCC tumours, CAIX expression is less frequent and more heterogeneous, thus it may not be
such an attractive target for immunotherapy. However, the association between CAIX and metastasis
makes it a plausible target as an adjuvant for metastasis-targeted immunotherapy. Since tumour cells
residing in hypoxic and acidic regions are associated with therapy resistance, it is conceivable that
these cells will express CAIX and that they will survive chemotherapy and/or radiotherapy and seed
metastatic outgrowths. While targeting CAIX in such cells is certainly an intriguing prospect, there are
only a few reported studies on the detection of CAIX in metastatic lesions [165–167], therefore more
evidence is needed to support this hypothesis.
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Our understanding of the function of CAIX in tumour pHe regulation has highlighted the
importance of mitochondrial energy metabolism in cancer. In parallel, several studies have suggested
that mitochondrial metabolism plays an important role in the development of drug resistance in
cancer [168,169]. It has been argued that resistant cancer cells are more dependent on mitochondrial
oxidative metabolism than glycolysis. In many haematological and solid tumours, treatment resistance
is associated with a shift towards an oxidative phosphorylation-dependent energetic status [60,170–172].
Resistant cells display higher levels of reactive oxygen species (ROS) and increased mitochondrial mass,
oxygen consumption, ATP production and fatty acid synthesis [173–175]. This metabolic adaptation
has been hypothesized as a strategy to meet the increased energetic demands of DNA repair, drug efflux
and detoxification. Furthermore, the inhibition of oxidative phosphorylation has been shown to
abrogate resistance to EGFR inhibitors in EGFR-driven lung cancers [176], docetaxel in prostate
cancer [177], MAPK inhibitors in melanoma [178] and 5-fluorouracil (5FU) in colon cancers [179].
Therefore, combining conventional chemotherapies with mitochondrial inhibitors (e.g., metformin,
tigecycline) represents a promising strategy [180]. In the context of CAIX and tumour pHe regulation,
it is tempting to speculate that the inhibition of mitochondrial respiration may reduce the acidifying
effect of CAIX on pHe.
10. Conclusions
Our understanding of tumour pH and its regulation has come a long way, since the landmark
discoveries of cancer cell metabolism by Otto Warburg, and the first in vivo measurements of tumour
intracellular and extracellular pH in solid tumours. The progress in recent decades in the fields of
cancer modelling, molecular biology, genetics, and in vivo imaging techniques has provided us with a
molecular-level understanding of acid-base homeostasis in cancer. Since its discovery in the early 1990s,
CAIX has emerged as an important pH regulator in solid tumours, with recent evidence demonstrating
that it functions as a pHe-stat. With increasing knowledge about the contribution of acidic pHe to
all steps of cancer development and progression, it is now evident that CAIX provides a selective
advantage to cancer cells by allowing them to create a hostile acidic environment in which they can
survive and thrive, but in which host cells cannot, and to acquire an invasive and metastatic phenotype.
The fact that CAIX-expressing cancer cells generally represent the most aggressive fraction of solid
tumours indicates a fertile avenue for clinical translation in terms of diagnosis, prognosis, and therapy.
It is unlikely, however, that targeting CAIX on its own will be sufficient to produce a meaningful clinical
benefit because of the phenotypic plasticity and redundancies in cellular pH regulatory mechanisms.
Probably, therefore, the greatest benefit of agents targeting CAIX would be realized by using them in
combination with other therapeutic agents in an adjuvant or neoadjuvant setting.
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